Washington Growth Strategies LLC Invests $397,000 in MiniMed Group Inc $MMED

Washington Growth Strategies LLC bought a new stake in MiniMed Group Inc (NASDAQ:MMED) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 26,587 shares of the company’s stock, valued at approximately $397,000.

A number of other hedge funds have also bought and sold shares of the business. Legal & General Group Plc purchased a new position in MiniMed Group in the second quarter worth $91,000. The Manufacturers Life Insurance Company bought a new stake in shares of MiniMed Group during the 2nd quarter worth $185,000. Punch & Associates Investment Management Inc. purchased a new position in shares of MiniMed Group in the 2nd quarter worth about $292,000. Deutsche Bank AG purchased a new position in shares of MiniMed Group in the 2nd quarter worth about $420,000. Finally, Bank of New York Mellon Corp bought a new position in MiniMed Group during the second quarter valued at about $1,058,000.

Key Stories Impacting MiniMed Group

Here are the key news stories impacting MiniMed Group this week:

• Positive Sentiment: Analysts see further upside: Citigroup and Wells Fargo issued forecasts calling for strong price appreciation, while analysts at Mizuho, UBS Group, Bank of America and BTIG Research also said MiniMed’s share price is expected to rise. The cluster of bullish views may support investor confidence and buying interest. Citigroup forecast Wells Fargo forecast Mizuho analyst view UBS analyst view Bank of America analyst view BTIG analyst view
• Positive Sentiment: New products are driving optimism: A recent product introduction helped lift MiniMed’s top line, with further launches scheduled over the coming months. Investors appear to be viewing the product pipeline as a potential source of sustained growth. Why MiniMed stock was soaring
• Positive Sentiment: Operational momentum is improving: Coverage highlights recurring revenue streams, regulatory progress and a strong beginning to fiscal 2027, reinforcing the case for more predictable growth. Recurring revenues and product cycle Fiscal 2027 progress
• Neutral Sentiment: Morgan Stanley raised its target: The firm increased its target from $19 to $21 and maintained an “overweight” rating. However, the new target remains below the referenced recent trading level, suggesting that some expected gains may already be reflected in the valuation.

MiniMed Group Price Performance

MiniMed Group stock opened at $23.28 on Friday. The firm has a 50 day simple moving average of $18.21. MiniMed Group Inc has a 1-year low of $10.65 and a 1-year high of $24.43. The stock has a market cap of $6.55 billion and a price-to-earnings ratio of -34.24.

MiniMed Group (NASDAQ:MMED) last posted its earnings results on Wednesday, June 3rd. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.46). The business had revenue of $837.00 million during the quarter. The company’s revenue was up 15.6% on a year-over-year basis. Equities research analysts anticipate that MiniMed Group Inc will post 0.7 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have commented on MMED shares. Wells Fargo & Company lifted their price objective on shares of MiniMed Group from $22.00 to $26.00 and gave the stock an “overweight” rating in a research report on Wednesday. Mizuho upped their price objective on MiniMed Group from $21.00 to $26.00 and gave the company an “outperform” rating in a research note on Wednesday. Morgan Stanley increased their price objective on MiniMed Group from $19.00 to $21.00 and gave the company an “overweight” rating in a report on Thursday. Piper Sandler restated a “neutral” rating and issued a $16.00 target price on shares of MiniMed Group in a research note on Thursday, June 4th. Finally, BTIG Research upped their price target on MiniMed Group from $25.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday. Thirteen analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $23.77.

MiniMed Group Profile

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.